Hidradenitis Suppurativa Market - Size, Share, Industry Trends, and Forecasts (2025-2032)

By Treatment Type:

Based on treatment type, the market is categorized into medications and surgical.

Trends in Type:

• There is growing demand for biologics, due to their efficacy in moderate-to-severe HS.
• There are advancements in surgical techniques such as minimally invasive procedures used to reduce scarring.

The medications segment accounted for the largest market share in 2024 and is expected to grow at the fastest CAGR over the forecast period.

• Medications are further categorized into antibiotics, biologics, corticosteroids, and others.
• Medications dominate the hidradenitis suppurativa market trends. Various medication classes are used to treat this chronic skin condition.
• Antibiotics, including tetracyclines, are commonly prescribed to control bacterial infections and reduce inflammation.
• Moreover, hormonal therapies, such as oral contraceptives and anti-androgens are used. They help manage the hormonal triggers associated with HS.
• Moreover, biologics such as adalimumab, target specific immune pathways. They are used for moderate to severe cases, which offer long-term control. The development of new biologics is driving the segment.
• For instance, in 2023, the FDA approved Cosentyx as a new biologic treatment for moderate to severe hidradenitis suppurativa (HS).
• Overall, as per the market analysis, accessibility, versatility, and advancements are driving a segment in hidradenitis suppurativa market growth.

By Stage:

Based on stage, the market is categorized into hurley stage I, hurley stage II, and hurley stage III.

Trends in the Stage:

• Hurley stage II represents a significant portion of the market due to its moderate severity, requiring a balance of topical, oral, and potentially some procedural interventions.
• Increasing focus on early intervention in stage I to prevent progression to more severe stages.

The hurley stage II segment accounted for the largest market share in 2024.

• Hurley stage II dominate the hidradenitis suppurativa market trends. It is characterized by painful lumps that frequently recur. It creates abscesses that drain foul-smelling discharge. It also does the formation of sinus tracts under the skin.
• Patients in this stage typically experience moderate disease progression. Symptoms are severe enough to seek medical intervention. This makes them a key focus for treatment options.
• Lifestyle factors, such as obesity and smoking are leading to the growing prevalence of hurley stage II.
• For instance, according to a study published by Springer Nature, in 2022, in the rising prevalence of HS, the majority of patients, approximately 45.9%, fall within the moderate Hurley stage II category.
• Overall, as per the market analysis, the rising prevalence of stage II HS is driving segmental growth in the hidradenitis suppurativa industry.

The hurley stage III segment is expected to grow at the fastest CAGR over the forecast period.

• Hurley stage III is emerging as an important segment in the market due to the increasing recognition of the severity and impact of advanced disease.
• Stage III is characterized by widespread interconnected sinus tracts. It develops significant scarring on the body. Also, it creates extensive abscesses that cause severe pain and functional impairment.
• This stage requires intensive treatment, including both medical and surgical interventions.This makes it a growing area of focus in HS care.
• Surgical procedures include wide excisions or laser therapy which involve higher costs and more complex care.
• As awareness of HS improves, healthcare providers are identifying more severe cases that have previously gone untreated. Additionally, it involves the identification of misdiagnosed cases as well. This will drive a segment for the forecasted period.

By End Use:

Based on end-use, the market is categorized into hospitals, dermatology clinics, and others. 

Trends in End-Use:

• The growing role of home healthcare providers in delivering post-operative care and medication management.
• Increasing adoption of digital health technologies, such as remote patient monitoring and mobile health applications, within clinical settings.

The hospitals segment accounted for the largest market share of 56.55% in 2024

• Hospitals dominate the market due to their ability to handle severe and complex cases. Patients with symptoms such as extensive abscesses, scarring, and sinus tracts necessitate specialized treatments.
• These include wide excision, laser therapy, and drainage surgical procedures, which are readily available only in hospitals.
• Moreover, hospitals play a critical role in the administration of biologic therapies. This requires monitoring for side effects and proper dosing.
• Growing populations, increased demand for specialized care, and government economic investment have led to a rise in the number of hospitals. This has improved the diagnostic and treatment capabilities, increasing patient access.
• For instance, according toFinancial Express, the number of hospitals in India increased by 27% from 2019 to 2024, rising from 30,000 to 38,000.
• Overall, as per the market analysis, increased accessibility by the growing number of hospitals across regions is driving segmental growth.

The dermatology clinics segment is expected to grow at the fastest CAGR over the forecast period.

• Dermatology clinics are emerging as a significant segment of the market. These clinics are becoming increasingly appealing to individuals who focus on outpatient care and non-invasive treatments.
• Patients value the shorter wait times and personalized attention provided in clinics compared to hospitals. This makes them an increasingly popular choice.
• Their ability to offer cost-effective treatments makes them a preferred option for patients with limited resources. This is contributing to their growing prominence in the market.
• According to market analysis, clinics are adopting advanced technologies, such as laser therapies. These are effective for treating localized lesions and minimizing scarring in HS patients.